
    
      Thirty-one chemotherapy-na—óve participants with asymptomatic metastatic androgen-independent
      prostate cancer will be enrolled and treated with intravenous (i.v.) IMC-A12 (Cixutumumab) at
      10 milligrams per kilogram (mg/kg) administered over 1 hour every 2 weeks. An additional 10
      participants will be enrolled and treated with IMC-A12 at a dose of 20 mg/kg every three
      weeks. Treatment will continue until evidence of disease progression or intolerable toxicity.
      Radiographic evaluation of response will be performed every 8 weeks for the participants
      treated with i.v. IMC-A12 at 20 mg/kg.
    
  